Drug Profile
REC 0438
Alternative Names: REC 0/0438Latest Information Update: 19 Nov 2019
Price :
$50
*
At a glance
- Originator Recordati
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Overactive bladder
Most Recent Events
- 15 Nov 2018 Recordati plans a proof of concept clinical trial for Overactive bladder (In children, In adolescents) in European Union (Recordati pipeline, November 2018)
- 28 Mar 2018 No recent reports of development identified for phase-I development in Overactive bladder in Italy (Intravesicular, Powder)
- 29 Jan 2018 Phase-I/II clinical trials in Overactive bladder in Portugal and Czech Republic (Intravesicular) (EudraCT2017-000905-19)